Latest News

Latest News

Redrawing the Limits of “Undruggable” Proteins

Redrawing the Limits of “Undruggable” Proteins

For most of modern target-based drug discovery's history, many biologically important targets have been sidelined as undruggable proteins: structural scaffolds and transcription factors with no active site to inhibit, proteins presenting flat surfaces with no pocket...

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

Weekly News Roundup | 10 August 2026

Weekly News Roundup | 10 August 2026

Life science news 10 August 2026: Curium pays up to $8 billion for Lantheus to build a radiopharma giant, AstraZeneca’s shares slide on reported $400 billion Bristol Myers Squibb talks, and the MHRA approves a first-in-class BTK inhibitor for chronic hives in an...

read more
Clinical Trials Roundup | 07 Aug 2026

Clinical Trials Roundup | 07 Aug 2026

Merck’s tulisokibart meets its primary and key secondary endpoints in a Phase 2 hidradenitis suppurativa study but misses in systemic sclerosis-associated interstitial lung disease, Eli Lilly’s olomorasib receives a second FDA Breakthrough Therapy designation in KRAS...

read more
Why AI Pilots Fail in Life Sciences

Why AI Pilots Fail in Life Sciences

Misaligned incentives, the wrong unit of work, and a probabilistic model where the process demands a reproducible one A draft annex to European GMP guidance, out for consultation until October 2025, contains the bluntest sentence yet written about AI in regulated...

read more
New Approach Methodologies: What Regulators Now Accept

New Approach Methodologies: What Regulators Now Accept

New approach methodologies have moved from the margins of preclinical science to the centre of regulatory policy. Since publishing its Roadmap to Reducing Animal Testing in Preclinical Safety Studies in April 2025, the United States Food and Drug Administration has...

read more
Evaluating Retrieval Systems for Clinical AI

Evaluating Retrieval Systems for Clinical AI

Clinical decision support is not new, and it does not have to be complex to work. If anything, the simpler it is, the more likely clinicians are to use it. The best-known earlier example is the WHO surgical safety checklist, developed by a team led by Atul Gawande,...

read more
CSRD Reporting: What Has Changed for European Biotech

CSRD Reporting: What Has Changed for European Biotech

The European Union has rewritten its sustainability disclosure rules. The consequences for the life sciences sector are substantial. CSRD reporting was once expected to capture tens of thousands of companies across the bloc. It now applies to a far smaller group of...

read more
Weekly News Roundup | 10 August 2026

Weekly News Roundup | 10 August 2026

Life science news 10 August 2026: Curium pays up to $8 billion for Lantheus to build a radiopharma giant, AstraZeneca’s shares slide on reported $400 billion Bristol Myers Squibb talks, and the MHRA approves a first-in-class BTK inhibitor for chronic hives in an...

read more
Clinical Trials Roundup | 07 Aug 2026

Clinical Trials Roundup | 07 Aug 2026

Merck’s tulisokibart meets its primary and key secondary endpoints in a Phase 2 hidradenitis suppurativa study but misses in systemic sclerosis-associated interstitial lung disease, Eli Lilly’s olomorasib receives a second FDA Breakthrough Therapy designation in KRAS...

read more
Why AI Pilots Fail in Life Sciences

Why AI Pilots Fail in Life Sciences

Misaligned incentives, the wrong unit of work, and a probabilistic model where the process demands a reproducible one A draft annex to European GMP guidance, out for consultation until October 2025, contains the bluntest sentence yet written about AI in regulated...

read more
New Approach Methodologies: What Regulators Now Accept

New Approach Methodologies: What Regulators Now Accept

New approach methodologies have moved from the margins of preclinical science to the centre of regulatory policy. Since publishing its Roadmap to Reducing Animal Testing in Preclinical Safety Studies in April 2025, the United States Food and Drug Administration has...

read more
Evaluating Retrieval Systems for Clinical AI

Evaluating Retrieval Systems for Clinical AI

Clinical decision support is not new, and it does not have to be complex to work. If anything, the simpler it is, the more likely clinicians are to use it. The best-known earlier example is the WHO surgical safety checklist, developed by a team led by Atul Gawande,...

read more
CSRD Reporting: What Has Changed for European Biotech

CSRD Reporting: What Has Changed for European Biotech

The European Union has rewritten its sustainability disclosure rules. The consequences for the life sciences sector are substantial. CSRD reporting was once expected to capture tens of thousands of companies across the bloc. It now applies to a far smaller group of...

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

Ziltivekimab ZEUS Trial: What the Null Result Means

Ziltivekimab ZEUS Trial: What the Null Result Means

The ziltivekimab ZEUS trial has produced one of the more instructive negative results in recent cardiovascular medicine. Novo Nordisk announced headline results on 31 July 2026 showing that its once-monthly interleukin-6 inhibitor ziltivekimab lowered inflammation...

read more
Singapore Radiopharmaceutical Market: How H2 2026 Looks

Singapore Radiopharmaceutical Market: How H2 2026 Looks

The Singapore radiopharmaceutical market enters the second half of 2026 with more clinical capacity, more research output and a heavier regulatory calendar than at any previous point. New imaging infrastructure came online at the end of 2025, first-in-human data from...

read more
Why True Health Foods Need Evidence, Not Fashion

Why True Health Foods Need Evidence, Not Fashion

Functional foods have entered the mainstream, but adding a recognised ingredient is not the same as creating a credible product. A cardiologist argues that the category’s next phase will be won on scientific rationale, dose and honest communication, not on the length...

read more
Weekly News Roundup | 03 August 2026

Weekly News Roundup | 03 August 2026

Life science news 3 August 2026: argenx pays $2.2 billion for what it calls a first-in-class anti-CD122 antibody, Johnson & Johnson strikes agreements worth up to $3.5 billion with in vivo CAR-T developer Sail Biomedicines, and GSK launches a £1.9 billion savings...

read more

Further News

Online Prescribing Is Moving Faster Than Regulation

Online prescribing has moved from being a relatively niche part of healthcare to an increasingly established route through which patients access treatment. That change brings clear benefits. Patients can seek treatment discreetly, access clinicians without travelling,...

Clinical Trials Roundup | 25 September 2026

The clinical trial results 25 September 2026 span Sjögren’s, urticaria, IgA nephropathy, obesity, cutaneous lupus and Alzheimer’s psychosis. Amgen’s dazodalibep met its primary endpoint in systemic Sjögren’s disease. Celldex’s barzolvolimab met its primary and all key...

Rethinking the Office: The Need for Healthier Buildings

For property owners, management companies, and business leaders, few sights are more unwelcome than an empty office building. Indoor air quality may be part of the answer to filling it. In the post-pandemic era, the home office has replaced the traditional workplace...

When Life Sciences Compliance Problems Are Really Operations Problems

When a life sciences organization struggles during a regulatory inspection or quality audit, the first reaction is fairly predictable: people point to evolving regulatory expectations, expanding documentation requirements, or the complexity of maintaining compliance...

Obesity Drug Access in the UK: NHS and Private Routes in 2026

Obesity drug access in the UK now runs along two tracks that rarely meet. One is a publicly funded NHS rollout of tirzepatide (Mounjaro), phased over as long as 12 years. The other is a private market that has grown far faster. A UCL survey estimates that about 1.6...

Transfusion Medicine in 2026: from Hemovigilance to Bedside Precision

Transfusion medicine plays a crucial role in modern healthcare by ensuring the availability of safe and compatible blood products for patients in need. Recognized globally as an essential medicine, blood remains the cornerstone of the healthcare workflow.  Every few...

Surgical Site Infections Can Consume Up to 75 Staff Hours

Surgical site infections can consume up to 75 staff hours and displace three operations, research finds A single surgical site infection (SSI) can consume an estimated 45 to 75 additional hours of healthcare staff time and create downstream demands equivalent to the...

Amylin Analogues Explained: The Next Obesity Drug Battleground

Amylin analogues have become one of the most active areas of obesity drug development. Novo Nordisk, Eli Lilly, Roche, Pfizer, AbbVie and AstraZeneca all hold clinical programmes built on the hormone amylin. The most advanced obesity candidate in the class, Novo...

The New Launch Model for the Agentic Era

Creating brand value when clinical information is no longer a differentiator The Life Sciences industry is undergoing seismic shifts: expanding drug pipelines, compressed launch timelines, and changing healthcare provider (HCP) and human capital expectations. HCPs...

Britain’s Nicotine Pouch Problem: What It Means for Oral Health

The UK Government has taken steps to combat smoking, and now nicotine pouches, through legislation, public health campaigns, youth prevention and support services. In the UK the age limit for smoking is 18 years old, meaning that individuals must be at least 18 to buy...

FUS-ALS Treatment Clears Phase 3 but the Figures Stay Unpublished

Ionis and Otsuka report a positive Phase 3 for ulefnersen, but the first FUS-ALS treatment arrives with one p value and no effect sizes.

    Why Business Fundamentals Belong in Every Life Sciences Career

    As a life scientist you might not have considered a business education. You are good at what you do, you may have no ambition to run a company or sit at a boardroom table. So why spend time on business fundamentals? The honest answer is that deep technical expertise...

    Want to Be Part of the Next Chapter in Life Sciences Media?

     

    LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

     

     

    Don’t wait for the media to pick up your story. Be the media.

    See More Articles

    Want to Be Part of the Next Chapter in Life Sciences Media?

     

    LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

     

     

    Don’t wait for the media to pick up your story. Be the media.